Dekkers CCJ, et al. - In a post-hoc analysis of a cross-over trial, authors probed into the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM-1, NGAL and LFABP) and inflammatory markers (urinary MCP-1 and IL-6) with the intention of yielding additional insight into kidney protective effects. In contrast with placebo, dapagliflozin decreased albuminuria by 43.9% and eGFR by 5.1mL/min/1.73m². The inference drawn was that the albuminuria-lowering effect of 6 weeks of dapagliflozin therapy could be due to decreased intraglomerular pressure or reduced tubular cell injury.